Drugs / Anti-CD123 CAR NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06690827 | Nov 2024 → Oct 2027 expected | CD4+/CD56+ hematodermic neoplasm, acute myeloid leukemia | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD123 CAR NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06690827 ↗ |
| Known as | antiCD123 CAR-NK | “antiCD123 CAR-NK therapy” NCT06690827 ↗ |
| Modality | Cell therapy | “CAR-NK cell therapy” NCT06690827 ↗ |